



Company Overview

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2014 amounted to \$20.3 billion, and approximately 5 billion in Q2 2015. For more information, visit www.tevapharm.com.

Operating Income⁽¹⁾ and Cash Flow: H1 2015




Stock Chart: (Rolling 12 months as of July 30 2015)




Net Revenues

(USD m)




Net Income (non GAAP¹)

(USD m)




Earnings Per Share (non GAAP)⁽¹⁾

(USD)



Dividends Per Share

(USD)



(1) See non GAAP reconciliation in our report for the (Second quarter of 2015)



Q2 2015 Business Highlights

- Strong cash flow from operations of \$1.5 billion, an increase of 41% compared to the second quarter of 2014. Free cash flow of \$1.3 billion, up 51% compared to the second quarter of 2014.
- Important clinical milestones for our migraine and movement disorders drug candidates:
 - TEV-48125 Phase IIb results show efficacy and safety in both episodic and chronic migraine; and
 - Positive top-line data from the first pivotal study of SD-809 for treatment of patients with Tardive Dyskinesia.
- Raising EPS guidance for full-year 2015 to \$5.15-5.40 from \$5.05-\$5.35.

On July 27, 2015, we announced that we had entered into a definitive agreement to acquire Allergan Generics for total consideration of \$40.5 billion comprised of \$33.75 billion in cash and Teva shares valued at \$6.75 billion. Teva expects the acquisition to close in the first quarter of 2016


Revenues by Markets and Segments

Q2 - 2015



Profit** by Segment

Q2 - 2015



* Other activities include our OTC business with P&G, distribution services primarily in Israel and Hungary, and sales of medical devices

** Profit consists of gross profit, less S&M and R&D expenses related to the segment. Segment profitability does not include G&A expenses, amortization and certain other items.

Teva Specialty pipeline

Phase 1	Phase 2	Phase 3	Registration
TV-46139 (abuse deterrent) Pain	Laquinimod Multiple sclerosis (progressive forms)	Laquinimod Multiple sclerosis (relapsing remitting)	CEP-33237 ER Hydrocodone (abuse deterrent) US Pain
SD-809 Tourette syndrome	Laquinimod Huntington disease	SD-809 Tardive dyskinesia	Copaxone® 40mg 3w ROW Multiple sclerosis
SD-560 Idiopathic pulmonary fibrosis	Pridopidine Huntington disease	TV-46763 (abuse deterrent) Pain	Copaxone® 20mg per Day Japan Multiple sclerosis
Reslizumab SC Asthma	TV-45070 Topical Neuropathic pain	Fluticasone Propionate MDPI Asthma	SD-809* Huntington Disease
Fluticasone Salmeterol (MDI) EU Asthma, COPD	TEV-48125 (anti CGRP) Chronic and episodic migraine	Fluticasone Salmeterol MDPI Asthma	Reslizumab IV Asthma
TEV-46017 (tidal inhaler) COPD	CEP-41750 (mesenchymal precursor cell) Acute myocardial infarction	QVAR® (BAI) US Asthma	Fluticasone Salmeterol Spiromax EU Asthma COPD
TEV-48108 (tidal inhaler) COPD	TV-1106 (Albutropin) – peds Growth hormone deficiency	CEP-41750 (mesenchymal precursor cell) Chronic heart failure	Bendamustine Rapid Infusion** CLL, NHL
TEV-90110 HIV		TV-1106 (Albutropin) – adults Growth hormone deficiency	
TEV-90111 HIV			
TEV-90112 HIV			
TEV-90113 HIV			

■ CNS & Pain
■ Respiratory
■ Other

* NDA pending file acceptance

** Filed by Eagle Pharmaceutical, commercialized by Teva

Note: Pipeline is correct as of July 2015. Phase 1 includes also projects designated for IND filing.